UT-MD Anderson Cancer Center: AACR - Combination Treatment is Well-Tolerated, Shows Antitumor Effects in KRAS G12C-Mutated Metastatic Colorectal Cancer
April 09, 2024
April 09, 2024
HOUSTON, Texas, April 9 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
MD Anderson researchers present results of targeted therapy with adagrasib plus cetuximab, leading to Phase III trials
* * *
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), . . .
* * *
MD Anderson researchers present results of targeted therapy with adagrasib plus cetuximab, leading to Phase III trials
* * *
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), . . .